Drug Profile
Research programme: antimicrobial agents - Agency for Science, Technology and Research/AstraZeneca
Latest Information Update: 28 Dec 2017
Price :
$50
*
At a glance
- Originator Agency for Science, Technology and Research; AstraZeneca
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gram-negative infections
Most Recent Events
- 28 Dec 2017 No recent reports of development identified for research development in Gram-negative-infections in Singapore
- 28 Dec 2017 No recent reports of development identified for research development in Gram-negative-infections in United Kingdom
- 04 Nov 2013 Early research in Gram-negative infections in Singapore and United Kingdom (unspecified route)